Matches in Wikidata for { <http://www.wikidata.org/entity/Q66346848> ?p ?o ?g. }
Showing items 1 to 77 of
77
with 100 items per page.
- Q66346848 description "clinical trial" @default.
- Q66346848 description "ensayu clínicu" @default.
- Q66346848 description "klinisch onderzoek" @default.
- Q66346848 description "клінічне випробування" @default.
- Q66346848 name "Open-label, Uncontrolled Phase II Trial of Intravenous PI3K Inhibitor BAY80-6946 in Patients With Relapsed, Indolent or Aggressive Non-Hodgkin's Lymphomas" @default.
- Q66346848 name "Open-label, Uncontrolled Phase II Trial of Intravenous PI3K Inhibitor BAY80-6946 in Patients With Relapsed, Indolent or Aggressive Non-Hodgkin's Lymphomas" @default.
- Q66346848 type Item @default.
- Q66346848 label "Open-label, Uncontrolled Phase II Trial of Intravenous PI3K Inhibitor BAY80-6946 in Patients With Relapsed, Indolent or Aggressive Non-Hodgkin's Lymphomas" @default.
- Q66346848 label "Open-label, Uncontrolled Phase II Trial of Intravenous PI3K Inhibitor BAY80-6946 in Patients With Relapsed, Indolent or Aggressive Non-Hodgkin's Lymphomas" @default.
- Q66346848 prefLabel "Open-label, Uncontrolled Phase II Trial of Intravenous PI3K Inhibitor BAY80-6946 in Patients With Relapsed, Indolent or Aggressive Non-Hodgkin's Lymphomas" @default.
- Q66346848 prefLabel "Open-label, Uncontrolled Phase II Trial of Intravenous PI3K Inhibitor BAY80-6946 in Patients With Relapsed, Indolent or Aggressive Non-Hodgkin's Lymphomas" @default.
- Q66346848 P1050 Q66346848-346F3EF9-21F4-4755-A856-86473E1277AD @default.
- Q66346848 P1132 Q66346848-E6DD402A-5405-461A-8838-0CB3A45F54B1 @default.
- Q66346848 P131 Q66346848-F690EE17-4DCF-4D57-8047-2F0B60FA1326 @default.
- Q66346848 P1476 Q66346848-284BE0D0-EB2D-4CFA-8E82-9EB9D46A41A7 @default.
- Q66346848 P17 Q66346848-07CE2A96-DA81-44A0-8F54-2E0E5B6DA155 @default.
- Q66346848 P17 Q66346848-09FEBB05-0D66-4773-93C7-C2A675DDB620 @default.
- Q66346848 P17 Q66346848-16D39D78-D447-4571-BEAE-BD831C33CEC0 @default.
- Q66346848 P17 Q66346848-2C311522-F9DC-41E4-B748-983A412414EF @default.
- Q66346848 P17 Q66346848-31559637-13D2-44AD-914C-B3B1FB62FAB1 @default.
- Q66346848 P17 Q66346848-48E0EEDB-0A45-467E-962F-A5972A5937C8 @default.
- Q66346848 P17 Q66346848-503FBC46-06BB-4215-91F6-DFBF0DE90835 @default.
- Q66346848 P17 Q66346848-534363C8-22DA-4BBD-B8E9-845FF09CAEC4 @default.
- Q66346848 P17 Q66346848-67AE5433-ABA3-4162-84B3-9D31E76B3E5E @default.
- Q66346848 P17 Q66346848-75D7EAF7-EB11-4156-B3E2-FF829546FE4B @default.
- Q66346848 P17 Q66346848-8DE0E9A9-DF24-4AFC-AA23-6407BE3C8575 @default.
- Q66346848 P17 Q66346848-902945B9-370A-422B-8687-4E5C2B16912E @default.
- Q66346848 P17 Q66346848-92FF2550-A830-4F74-B669-313F1B450AAE @default.
- Q66346848 P17 Q66346848-93DBB4E6-7636-4963-91FC-73A3DBA74E4D @default.
- Q66346848 P17 Q66346848-95CA1E86-E305-4882-8AE1-B527A9D6363B @default.
- Q66346848 P17 Q66346848-9F8E8BAC-EC01-455C-812D-4C4E70C561B9 @default.
- Q66346848 P17 Q66346848-A79CE0D9-F6B9-45F8-BE3A-9FCD5E417AEA @default.
- Q66346848 P17 Q66346848-C5F7F2A0-FB90-4B2A-BDB7-308721F5D176 @default.
- Q66346848 P17 Q66346848-CD1E553D-7A09-480B-AFF1-527EB3D4F0F3 @default.
- Q66346848 P17 Q66346848-D3752919-2AD0-4EAB-B04B-BA04A58C7E69 @default.
- Q66346848 P17 Q66346848-EFD34163-DDC4-4EB1-86DA-0C831158E5A2 @default.
- Q66346848 P17 Q66346848-F0A661E5-C3DD-4049-ADD1-51949CD273E2 @default.
- Q66346848 P2899 Q66346848-BA91B8CC-BFF4-4796-8769-F0F8FC6D4341 @default.
- Q66346848 P3098 Q66346848-AF215C37-6850-4C4A-BC84-70A0C25622ED @default.
- Q66346848 P31 Q66346848-79F969E2-3005-4969-AA09-18AF4299DDE2 @default.
- Q66346848 P580 Q66346848-C0067194-3BB8-4392-BBD5-F05337B16EC9 @default.
- Q66346848 P582 Q66346848-7DEAFC54-A9C4-456F-85CA-9B11D95C4B7F @default.
- Q66346848 P6099 Q66346848-22A2C968-A0F9-424F-9508-940CD826AB44 @default.
- Q66346848 P8363 Q66346848-E686B709-F85D-47D8-A584-DACD2FB7F73C @default.
- Q66346848 P1050 Q208414 @default.
- Q66346848 P1132 "+227" @default.
- Q66346848 P131 Q8646 @default.
- Q66346848 P1476 "Open-label, Uncontrolled Phase II Trial of Intravenous PI3K Inhibitor BAY80-6946 in Patients With Relapsed, Indolent or Aggressive Non-Hodgkin's Lymphomas" @default.
- Q66346848 P17 Q142 @default.
- Q66346848 P17 Q145 @default.
- Q66346848 P17 Q16 @default.
- Q66346848 P17 Q183 @default.
- Q66346848 P17 Q219 @default.
- Q66346848 P17 Q27 @default.
- Q66346848 P17 Q28 @default.
- Q66346848 P17 Q29 @default.
- Q66346848 P17 Q30 @default.
- Q66346848 P17 Q31 @default.
- Q66346848 P17 Q33 @default.
- Q66346848 P17 Q334 @default.
- Q66346848 P17 Q34 @default.
- Q66346848 P17 Q36 @default.
- Q66346848 P17 Q38 @default.
- Q66346848 P17 Q40 @default.
- Q66346848 P17 Q408 @default.
- Q66346848 P17 Q41 @default.
- Q66346848 P17 Q43 @default.
- Q66346848 P17 Q45 @default.
- Q66346848 P17 Q664 @default.
- Q66346848 P17 Q801 @default.
- Q66346848 P2899 "+18" @default.
- Q66346848 P3098 "NCT01660451" @default.
- Q66346848 P31 Q30612 @default.
- Q66346848 P580 "2012-11-19T00:00:00Z" @default.
- Q66346848 P582 "2016-06-22T00:00:00Z" @default.
- Q66346848 P6099 Q42824440 @default.
- Q66346848 P8363 Q78089383 @default.